<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22371650</article-id><article-id pub-id-type="pmc">3282601</article-id><article-id pub-id-type="doi">10.2147/COPD.S27480</article-id><article-id pub-id-type="publisher-id">copd-7-095</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Lung function decline in COPD</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tantucci</surname><given-names>Claudio</given-names></name><xref ref-type="corresp" rid="c1-copd-7-095"/></contrib><contrib contrib-type="author"><name><surname>Modina</surname><given-names>Denise</given-names></name></contrib><aff id="af1-copd-7-095">Unit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy</aff></contrib-group><author-notes><corresp id="c1-copd-7-095">Correspondence: Claudio Tantucci, Clinica di Medicina Interna I, Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25100 Brescia, Italy, Tel +39 030 39 80 69, Fax +39 030 39 80 69, Email <email>tantucci@med.unibs.it</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub--><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>09</day><month>2</month><year>2012</year></pub-date><volume>7</volume><fpage>95</fpage><lpage>99</lpage><permissions><copyright-statement>&#x000a9; 2012 Tantucci and Modina, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2012</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The landmark study of Fletcher and Peto on the natural history of tobacco smoke-related chronic airflow obstruction suggested that decline in the forced expiratory volume in the first second (FEV<sub>1</sub>) in chronic obstructive pulmonary disease (COPD) is slow at the beginning, becoming faster with more advanced disease. The present authors reviewed spirometric data of COPD patients included in the placebo arms of recent clinical trials to assess the lung function decline of each stage, defined according to the severity of airflow obstruction as proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. In large COPD populations the mean rate of FEV<sub>1</sub> decline in GOLD stages II and III is between 47 and 79 mL/year and 56 and 59 mL/year, respectively, and lower than 35 mL/year in GOLD stage IV. Few data on FEV<sub>1</sub> decline are available for GOLD stage I. Hence, the loss of lung function, assessed as expiratory airflow reduction, seems more accelerated and therefore more relevant in the initial phases of COPD. To have an impact on the natural history of COPD, it is logical to look at the effects of treatment in the earlier stages.</p></abstract><kwd-group><kwd>chronic obstructive pulmonary disease</kwd><kwd>decline</kwd><kwd>forced expiratory volume in 1 second</kwd><kwd>FEV<sub>1</sub></kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Assumptions about lung function decline occurring in chronic obstructive pulmonary disease (COPD) have been greatly influenced by the landmark study of Fletcher and Peto<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> on the natural history of tobacco smoke&#x02013;related chronic airflow obstruction.<xref ref-type="bibr" rid="b2-copd-7-095">2</xref> More than 30 years ago, Fletcher and Peto<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> measured the forced expiratory volume in 1 second (FEV<sub>1</sub>) every 6 months for an 8-year follow-up period in a cohort of 792 working men, drawing the well-known graph of FEV<sub>1</sub> decline over time in COPD (<xref ref-type="fig" rid="f1-copd-7-095">Figure 1</xref>). FEV<sub>1</sub> was originally expressed as a percentage of the value calculated by extrapolation back to the age of 25 years, made equal to 100, and time in years from age 25 to age 75.</p><p>A lot of information arose from Fletcher and Peto&#x02019;s<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> pioneering work: the individual susceptibility to smoking-related lung functional damage, the unavoidable progression of the airflow obstruction once COPD is established, the large variability of the abnormal lung function decline among different subjects, the possible reduction of the excessive FEV<sub>1</sub> decline after smoking cessation at all times, and the paucity of self-reported symptoms when the airflow reduction is mild to moderate. However, among the various messages offered by their analysis, the most retained was that the rate of FEV<sub>1</sub> decline increased progressively with time in susceptible smokers. In other words, in the COPD patients who smoked, the lower the FEV<sub>1</sub>, the greater its subsequent decline for similar intervals of time.</p><p>Some limitations must be acknowledged in the work of Fletcher and Peto.<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> All subjects were male, their recruitment age was between 30 and 59 years only, and the follow-up period was relatively short compared with the large time range shown on the x-axis of Fletcher and Peto&#x02019;s<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> graph (<xref ref-type="fig" rid="f1-copd-7-095">Figure 1</xref>). Therefore, the curves shown in the graph were largely extrapolated backward and forward with inherent inaccuracies, possibly leading to an erroneous picture of the phenomenon. Because of this, the present authors believe that a false idea of lung function decline in COPD has been inculcated in pulmonologists, suggesting that the disease progresses slowly at the beginning and that the loss of function markedly increases only when a given degree of severity has been reached. As a consequence, major therapeutic efforts have been focused on severe to very severe airflow obstruction in COPD patients. Recently, large amounts of data have been collected to challenge Fletcher and Peto&#x02019;s<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> hypothesis.</p><p>In the framework of the classification of airflow obstruction severity proposed by Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines,<xref ref-type="bibr" rid="b3-copd-7-095">3</xref> the authors analyzed the spirometric data of COPD patients enrolled in recent prospective clinical trials and randomized in the placebo arms to assess the natural rate of FEV<sub>1</sub> decline of each stage.</p></sec><sec sec-type="methods"><title>Methods</title><p>The authors searched the PubMed database and collected the data available after 1990 on the average rate of FEV<sub>1</sub> decline found in large observational studies and in recently published prospective randomized control trials on COPD patients and measured in the respective placebo arms with a follow-up of at least 3 years.</p></sec><sec sec-type="results"><title>Results</title><p>The most important data concerning the average rate of FEV<sub>1</sub> decline prospectively measured in large COPD cohorts are shown in <xref ref-type="table" rid="t1-copd-7-095">Table 1</xref>.</p><p>Only one large study was found about COPD patients with FEV<sub>1</sub> higher than 80% of the predicted value (GOLD stage I). A total of 430 COPD patients recruited in the first stage of the Swiss Study on Air Pollution and Lung Diseases in Adults exhibited an average annual decline in FEV<sub>1</sub> of about 40 mL/year over 11 years.<xref ref-type="bibr" rid="b4-copd-7-095">4</xref> Within this cohort, the subgroup of asymptomatic patients had a slightly slower decline than those with chronic cough and phlegm.<xref ref-type="bibr" rid="b4-copd-7-095">4</xref> A much smaller cohort of GOLD stage I and II COPD patients was followed for 3 years in the Copenhagen City Heart Study,<xref ref-type="bibr" rid="b5-copd-7-095">5</xref> and this cohort showed a similar annual reduction in FEV<sub>1</sub>. Further studies are urgently needed to establish firmly how FEV<sub>1</sub> declines in GOLD stage I COPD patients. Data collected on COPD patients recruited in GOLD stage II (with FEV<sub>1</sub> between 79% and 50% of the predicted value) by Anthonisen et al (for the Lung Health Study [LHS]),<xref ref-type="bibr" rid="b6-copd-7-095">6</xref> Pauwels et al,<xref ref-type="bibr" rid="b7-copd-7-095">7</xref> Anthonisen et al (for the LHS-3),<xref ref-type="bibr" rid="b8-copd-7-095">8</xref> the LHS Research Group,<xref ref-type="bibr" rid="b9-copd-7-095">9</xref> and Jenkins et al<xref ref-type="bibr" rid="b10-copd-7-095">10</xref> are consistent, reporting a mean annual FEV<sub>1</sub> decline of 56, 69, 53, 47, and 60 mL/year, respectively. However, it should be noted that in the post hoc analysis from the TORCH (TOwards a Revolution in COPD Health) study the placebo group did not faithfully represent the whole of GOLD stage II, because the inclusion criteria required a pre-bronchodilator FEV<sub>1</sub> value of less than 60% of the predicted value.<xref ref-type="bibr" rid="b10-copd-7-095">10</xref> Accordingly, the COPD patients included in this placebo group had a baseline pre-bronchodilator FEV<sub>1</sub> between 60% and 50% of the predicted value. Recently published data in the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study showed a decline in the placebo group greater than that found in previous studies, in average amounting to 79 mL/year.<xref ref-type="bibr" rid="b11-copd-7-095">11</xref> A secondary analysis of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study evaluated the effects of long-term treatment with tiotropium in GOLD stage II COPD patients.<xref ref-type="bibr" rid="b12-copd-7-095">12</xref> Pre-bronchodilator FEV<sub>1</sub> declined by a mean of 49 mL/year in the control group. However, this group was not a true placebo group, because all respiratory medications, except other inhaled anticholinergic drugs, were allowed during the trial and about 65% of these patients in the control arm were taking two active drugs. Because of this, the lower mean FEV<sub>1</sub> decline in the UPLIFT control group cannot be considered as truly representative of GOLD stage II COPD. Therefore, it is reasonable to estimate that the mean post-bronchodilator FEV<sub>1</sub> decline of GOLD stage II COPD patients amounts to 61 &#x000b1; 12 mL/year, with a little bias toward the lowest initial FEV<sub>1</sub> values in this stage. Lung function decline of COPD patients recruited in GOLD stage III is much better defined. In fact, Jenkins et al<xref ref-type="bibr" rid="b10-copd-7-095">10</xref> and Burge et al<xref ref-type="bibr" rid="b13-copd-7-095">13</xref> had very homogeneous data with a mean FEV<sub>1</sub> decline from 56 to 59 mL/year. Interestingly, the FEV<sub>1</sub> decline reported by Anzueto et al<xref ref-type="bibr" rid="b14-copd-7-095">14</xref> in a 1-year follow-up study performed in the same stage of COPD severity amounted in the placebo arm to 58 mL/year. The average FEV<sub>1</sub> decline found by Decramer et al<xref ref-type="bibr" rid="b12-copd-7-095">12</xref> in GOLD stage III in the control arm of the UPLIFT study, amounting to 38 mL/year, is likely underestimated for the same reason mentioned above. A few data available about COPD patients recruited with FEV<sub>1</sub> less than 30% of the predicted value have shown a much slower mean FEV<sub>1</sub> decline at GOLD stage IV than at other stages.<xref ref-type="bibr" rid="b10-copd-7-095">10</xref>,<xref ref-type="bibr" rid="b12-copd-7-095">12</xref></p><p>Dawkins et al<xref ref-type="bibr" rid="b15-copd-7-095">15</xref> published interesting data about lung function decline in patients with alpha-1-antitrypsin deficiency-related emphysema stratified according to the GOLD guidelines (<xref ref-type="table" rid="t2-copd-7-095">Table 2</xref>). In emphysematous COPD patients with the PiZ phenotype, the mean annual FEV<sub>1</sub> decline was higher in moderate disease, corresponding to GOLD stage II, and was greater than in the general COPD population. These data suggest that COPD patients suffering from panlobular emphysema have the highest rate of FEV<sub>1</sub> decline occurring in the early phase of the disease. This has also been reported by Vestbo et al<xref ref-type="bibr" rid="b16-copd-7-095">16</xref> in a recently published paper on the change in FEV<sub>1</sub> over time in the large COPD population enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational study. In this study patients with computerized tomography scan evidence of emphysema exhibited the largest rate of FEV<sub>1</sub> decline over a 3-year follow-up period.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>According to the evidence produced, it is clear that the loss of lung function, assessed as expiratory airflow reduction, is more accelerated and therefore more relevant in the early stages of COPD than in the late stages, with some reservation regarding GOLD stage I where consistent information is still lacking. Therefore, a different trend of the FEV<sub>1</sub> decline in COPD can be envisaged (<xref ref-type="fig" rid="f2-copd-7-095">Figure 2</xref>), showing an opposite view to that of Fletcher and Peto&#x02019;s diagram (<xref ref-type="fig" rid="f1-copd-7-095">Figure 1</xref>). This is likely because COPD patients in the early stages have more to lose than those in the most advanced stage. In addition, some of the FEV<sub>1</sub> loss can be partly buffered by the increase in total lung capacity in GOLD stage IV COPD patients.</p><p>Based on these findings, it seems that any attempt to positively interfere with the natural history of COPD by using different therapeutic options should logically be focused on COPD patients in at least GOLD stage II. This is suggested by the subgroup analysis of the treatment group in the GOLD stage II COPD patients of the UPLIFT study.<xref ref-type="bibr" rid="b12-copd-7-095">12</xref> Of course, this approach should be tested and proved by adequate randomized clinical trials.<xref ref-type="bibr" rid="b17-copd-7-095">17</xref></p><p>It must be acknowledged that most of the recent large COPD trials studied had a 3- to 4-year follow-up period, which is much shorter than the follow-up period in Fletcher and Peto&#x02019;s<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> analysis; this could be a limitation in the accuracy of the FEV<sub>1</sub> decline.</p><p>Furthermore, in many of these studies the percentage of dropouts was higher in the placebo arm, meaning that the average rate of FEV<sub>1</sub> decline of healthier COPD patients is known rather than that of the true COPD population. As a consequence, the natural rate of FEV<sub>1</sub> decline could be underestimated by the existing data. It is reasonable that this could be accentuated in the sicker COPD patients recruited in GOLD stage IV. However, the withdrawal from these studies is essentially because of symptoms and/or exacerbations. Since FEV<sub>1</sub> is poorly related to symptoms<xref ref-type="bibr" rid="b18-copd-7-095">18</xref> and even to exacerbations,<xref ref-type="bibr" rid="b19-copd-7-095">19</xref> it is plausible that this reasoning may similarly be applied to each COPD stage, leaving the message of a greater loss of function in the early phase of the disorder still valid.</p><p>Finally, it should be recognized that the natural history of lung function, not only in healthy never smokers and smokers but also in COPD patients, has been essentially assessed in terms of expiratory airflow reduction, looking at the FEV<sub>1</sub> annual change as the primary measure to track the progressive decline of lung function. This could be a limitation, especially in very sick patients.</p></sec><sec><title>Conclusion</title><p>In summary, the authors have shown that information provided in recent years about the rate of FEV<sub>1</sub> decline in COPD patients strongly supports the concept that the faster progression of functional impairment in COPD occurs early and it particularly occurs in GOLD stage II. This is in contrast with Fletcher and Peto&#x02019;s<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> analysis. In the present authors&#x02019; view it seems more logical to make efforts for an early (spirometric) detection of COPD, based on risk factors rather than symptoms, and to plan randomized clinical trials to show the efficacy of an early strategy of intervention on the natural history of such a disorder.</p></sec></body><back><fn-group><fn id="fn1-copd-7-095"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-7-095"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>C</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name></person-group><article-title>The natural history of chronic airflow obstruction</article-title><source>Br Med J</source><year>1977</year><volume>1</volume><issue>6077</issue><fpage>1645</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">871704</pub-id></element-citation></ref><ref id="b2-copd-7-095"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>C</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Tinker</surname><given-names>CM</given-names></name><name><surname>Speizer</surname><given-names>FE</given-names></name></person-group><source>The Natural History of Chronic Bronchitis and Emphysema</source><publisher-loc>London</publisher-loc><publisher-name>Oxford University Press</publisher-name><year>1976</year></element-citation></ref><ref id="b3-copd-7-095"><label>3</label><element-citation publication-type="book"><collab>Global Initiative for Chronic Obstructive Lung Disease</collab><source>Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>National Heart, Lung and Blood Institute</publisher-name><month>4</month><year>2001</year><comment>(revised 2007)</comment></element-citation></ref><ref id="b4-copd-7-095"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridevaux</surname><given-names>PO</given-names></name><name><surname>Gerbase</surname><given-names>MW</given-names></name><name><surname>Probst-Hensch</surname><given-names>NM</given-names></name><name><surname>Schindler</surname><given-names>C</given-names></name><name><surname>Gaspoz</surname><given-names>JM</given-names></name><name><surname>Rochat</surname><given-names>T</given-names></name></person-group><article-title>Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD</article-title><source>Thorax</source><year>2008</year><volume>63</volume><issue>9</issue><fpage>768</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">18505800</pub-id></element-citation></ref><ref id="b5-copd-7-095"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>T</given-names></name><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Brix</surname><given-names>A</given-names></name><name><surname>Torre</surname><given-names>P</given-names></name><name><surname>Viskum</surname><given-names>K</given-names></name></person-group><article-title>Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial</article-title><source>Lancet</source><year>1999</year><volume>353</volume><issue>9167</issue><fpage>1819</fpage><lpage>1823</lpage><pub-id pub-id-type="pmid">10359405</pub-id></element-citation></ref><ref id="b6-copd-7-095"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Kiley</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Effects of smoking intervention and the use of an inhaled anticholinergic broncodilator on the rate of decline of FEV1: the Lung Health Study</article-title><source>JAMA</source><year>1994</year><volume>272</volume><issue>19</issue><fpage>1497</fpage><lpage>1505</lpage><pub-id pub-id-type="pmid">7966841</pub-id></element-citation></ref><ref id="b7-copd-7-095"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>L&#x000f6;fdhal</surname><given-names>CG</given-names></name><name><surname>Laitinen</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society study on chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><issue>25</issue><fpage>1948</fpage><lpage>1953</lpage><pub-id pub-id-type="pmid">10379018</pub-id></element-citation></ref><ref id="b8-copd-7-095"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Murray</surname><given-names>RP</given-names></name></person-group><article-title>Smoking and lung function of Lung Health Study participants after 11 years</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><issue>5</issue><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">12204864</pub-id></element-citation></ref><ref id="b9-copd-7-095"><label>9</label><element-citation publication-type="journal"><collab>Lung Health Study Research Group</collab><article-title>Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>26</issue><fpage>1902</fpage><lpage>1909</lpage><pub-id pub-id-type="pmid">11136260</pub-id></element-citation></ref><ref id="b10-copd-7-095"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>CR</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Calverly</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study</article-title><source>Respir Res</source><year>2009</year><volume>10</volume><fpage>59</fpage><pub-id pub-id-type="pmid">19566934</pub-id></element-citation></ref><ref id="b11-copd-7-095"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapperre</surname><given-names>TS</given-names></name><name><surname>Snoeck-Stroband</surname><given-names>JB</given-names></name><name><surname>Gosman</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease</article-title><source>Ann Intern Med</source><year>2009</year><volume>151</volume><issue>8</issue><fpage>517</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">19841453</pub-id></element-citation></ref><ref id="b12-copd-7-095"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name><name><surname>Lystig</surname><given-names>T</given-names></name><name><surname>Mehra</surname><given-names>S</given-names></name><name><surname>Tashkin</surname><given-names>DP</given-names></name></person-group><article-title>Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial</article-title><source>Lancet</source><year>2009</year><volume>374</volume><issue>9696</issue><fpage>1171</fpage><lpage>1178</lpage><pub-id pub-id-type="pmid">19716598</pub-id></element-citation></ref><ref id="b13-copd-7-095"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Maslen</surname><given-names>TK</given-names></name></person-group><article-title>Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial</article-title><source>BMJ</source><year>2000</year><volume>320</volume><issue>7245</issue><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">10807619</pub-id></element-citation></ref><ref id="b14-copd-7-095"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Tashkin</surname><given-names>D</given-names></name><name><surname>Menjoge</surname><given-names>S</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name></person-group><article-title>One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium</article-title><source>Pulm Pharmacol Ther</source><year>2005</year><volume>18</volume><issue>2</issue><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">15649848</pub-id></element-citation></ref><ref id="b15-copd-7-095"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawkins</surname><given-names>PA</given-names></name><name><surname>Dawkins</surname><given-names>CL</given-names></name><name><surname>Wood</surname><given-names>AM</given-names></name><name><surname>Nightingale</surname><given-names>PG</given-names></name><name><surname>Stockley</surname><given-names>JA</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>Rate of progression of lung function impairment in alpha1- antitrypsin deficiency</article-title><source>Eur Respir J</source><year>2009</year><volume>33</volume><issue>6</issue><fpage>1338</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">19164359</pub-id></element-citation></ref><ref id="b16-copd-7-095"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>LD</given-names></name><name><surname>Scanlon</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Changes in forced expiratory volume in 1 second over time in COPD</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>13</issue><fpage>1184</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">21991892</pub-id></element-citation></ref><ref id="b17-copd-7-095"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><article-title>Treatment of COPD: the sooner the better?</article-title><source>Thorax</source><year>2010</year><volume>65</volume><issue>9</issue><fpage>837</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">20805184</pub-id></element-citation></ref><ref id="b18-copd-7-095"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>RJ</given-names></name><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name></person-group><article-title>Pulmonary rehabilitation in chronic respiratory insufficiency: 7. Health-related quality of life among patients with chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>1994</year><volume>49</volume><issue>2</issue><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">8128407</pub-id></element-citation></ref><ref id="b19-copd-7-095"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Susceptibility to exacerbation in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>12</issue><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">20843247</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-copd-7-095" position="float"><label>Figure 1</label><caption><p>Modified version of Fletcher and Peto&#x02019;s<xref ref-type="bibr" rid="b1-copd-7-095">1</xref> graph showing the decline in the forced expiratory volume in the first second (FEV<sub>1</sub>).</p></caption><graphic xlink:href="copd-7-095f1"/></fig><fig id="f2-copd-7-095" position="float"><label>Figure 2</label><caption><p>Range of average rate of decline in the forced expiratory volume in the first second (FEV<sub>1</sub>) of chronic obstructive pulmonary disease patients according to initial severity of airflow reduction.</p><p><bold>Notes:</bold> The dashed segment of the line highlights any stage or part of it where consistent information is still lacking; control data from the UPLIFT (understanding Potential Long-term Impacts on Function with Tiotropium) study were not considered in the analysis.</p><p><bold>Abbreviation:</bold> yr, year.</p></caption><graphic xlink:href="copd-7-095f2"/></fig><table-wrap id="t1-copd-7-095" position="float"><label>Table 1</label><caption><p>Rate of annual decline in the forced expiratory volume in the first second (FEV<sub>1</sub>) recorded in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I&#x02013;IV chronic obstructive pulmonary disease patients randomized in the control arm during longitudinal studies with a follow-up period of at least 3 years</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Reference</th><th align="left" valign="top" rowspan="1" colspan="1">Study</th><th align="left" valign="top" rowspan="1" colspan="1">GOLD stage</th><th align="left" valign="top" rowspan="1" colspan="1">Patients (n)</th><th align="left" valign="top" rowspan="1" colspan="1">Age range (yr)</th><th align="left" valign="top" rowspan="1" colspan="1">Follow-up period (yr)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean FEV<sub>1</sub> decline (mL/yr)<xref ref-type="table-fn" rid="tfn3-copd-7-095">*</xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Bridevaux et al<xref ref-type="bibr" rid="b4-copd-7-095">4</xref></td><td align="left" valign="top" rowspan="1" colspan="1">SAPALDIA 1</td><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">430</td><td align="left" valign="top" rowspan="1" colspan="1">18&#x02013;60</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">40 &#x000b1; 37<xref ref-type="table-fn" rid="tfn4-copd-7-095">&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vestbo et al<xref ref-type="bibr" rid="b5-copd-7-095">5</xref></td><td align="left" valign="top" rowspan="1" colspan="1">CCHS</td><td align="left" valign="top" rowspan="1" colspan="1">I&#x02013;II</td><td align="left" valign="top" rowspan="1" colspan="1">145</td><td align="left" valign="top" rowspan="1" colspan="1">59 &#x000b1; 10<xref ref-type="table-fn" rid="tfn2-copd-7-095">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">42<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anthonisen et al<xref ref-type="bibr" rid="b6-copd-7-095">6</xref></td><td align="left" valign="top" rowspan="1" colspan="1">LHS</td><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">1964</td><td align="left" valign="top" rowspan="1" colspan="1">35&#x02013;60</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">56<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pauwels et al<xref ref-type="bibr" rid="b7-copd-7-095">7</xref></td><td align="left" valign="top" rowspan="1" colspan="1">EUROSCOP</td><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">643</td><td align="left" valign="top" rowspan="1" colspan="1">30&#x02013;65</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">69<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anthonisen et al<xref ref-type="bibr" rid="b8-copd-7-095">8</xref></td><td align="left" valign="top" rowspan="1" colspan="1">LHS-3</td><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">1357</td><td align="left" valign="top" rowspan="1" colspan="1">30&#x02013;60</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">53<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LHS Research Group<xref ref-type="bibr" rid="b9-copd-7-095">9</xref></td><td align="left" valign="top" rowspan="1" colspan="1">LHS-2</td><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">557</td><td align="left" valign="top" rowspan="1" colspan="1">40&#x02013;69</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">47<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jenkins et al<xref ref-type="bibr" rid="b10-copd-7-095">10</xref></td><td align="left" valign="top" rowspan="1" colspan="1">TORCH</td><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">535</td><td align="left" valign="top" rowspan="1" colspan="1">40&#x02013;80</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">60<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lapperre et al<xref ref-type="bibr" rid="b11-copd-7-095">11</xref></td><td align="left" valign="top" rowspan="1" colspan="1">GLUCOLD</td><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">45&#x02013;75</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">79<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Decramer et al<xref ref-type="bibr" rid="b12-copd-7-095">12</xref></td><td align="left" valign="top" rowspan="1" colspan="1">UPLIFT</td><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">1355</td><td align="left" valign="top" rowspan="1" colspan="1">64 &#x000b1; 9<xref ref-type="table-fn" rid="tfn2-copd-7-095">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">49<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Burge et al<xref ref-type="bibr" rid="b13-copd-7-095">13</xref></td><td align="left" valign="top" rowspan="1" colspan="1">ISOLDE</td><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1">375</td><td align="left" valign="top" rowspan="1" colspan="1">40&#x02013;75</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">59<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jenkins et al<xref ref-type="bibr" rid="b10-copd-7-095">10</xref></td><td align="left" valign="top" rowspan="1" colspan="1">TORCH</td><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1">775</td><td align="left" valign="top" rowspan="1" colspan="1">40&#x02013;80</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">56<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Decramer et al<xref ref-type="bibr" rid="b12-copd-7-095">12</xref></td><td align="left" valign="top" rowspan="1" colspan="1">UPLIFT</td><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1">1331</td><td align="left" valign="top" rowspan="1" colspan="1">65 &#x000b1; 8<xref ref-type="table-fn" rid="tfn2-copd-7-095">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">38<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jenkins et al<xref ref-type="bibr" rid="b10-copd-7-095">10</xref></td><td align="left" valign="top" rowspan="1" colspan="1">TORCH</td><td align="left" valign="top" rowspan="1" colspan="1">IV</td><td align="left" valign="top" rowspan="1" colspan="1">214</td><td align="left" valign="top" rowspan="1" colspan="1">40&#x02013;80</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">34<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Decramer et al<xref ref-type="bibr" rid="b12-copd-7-095">12</xref></td><td align="left" valign="top" rowspan="1" colspan="1">UPLIFT</td><td align="left" valign="top" rowspan="1" colspan="1">IV</td><td align="left" valign="top" rowspan="1" colspan="1">271</td><td align="left" valign="top" rowspan="1" colspan="1">63 &#x000b1; 8<xref ref-type="table-fn" rid="tfn2-copd-7-095">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">23<xref ref-type="table-fn" rid="tfn5-copd-7-095">&#x02020;&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-7-095"><p><bold>Notes:</bold></p></fn><fn id="tfn2-copd-7-095"><label>&#x000a7;</label><p>Mean age plus or minus the standard deviation;</p></fn><fn id="tfn3-copd-7-095"><label>*</label><p>standard deviation is shown when available;</p></fn><fn id="tfn4-copd-7-095"><label>&#x02020;</label><p>pre-bronchodilator FEV<sub>1</sub>;</p></fn><fn id="tfn5-copd-7-095"><label>&#x02020;&#x02020;</label><p>post-bronchodilator FEV<sub>1</sub>.</p></fn><fn id="tfn6-copd-7-095"><p><bold>Abbreviations:</bold> CCHS, Copenhagen City Heart Study; EUROSCOP, European Respiratory Society Study on Chronic Obstructive Pulmonary Disease; GLUCOLD, Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease study; ISOLDE, Inhaled Steroids in Obstructive Lung DiseasE study; LHS, Lung Health Study; LHS-2, Lung Health Study 2; LHS-3, Lung Health Study 3; SAPALDIA 1, first stage of the Swiss Study on Air Pollution and Lung Diseases in Adults; TORCH, TOwards a Revolution in COPD Health study; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium study; yr, year.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-7-095" position="float"><label>Table 2</label><caption><p>Rate of annual decline of the forced expiratory volume in the first second (FEV<sub>1</sub>) in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I&#x02013;IV chronic obstructive pulmonary disease patients with alpha-1-antitrypsin deficiency-related emphysema measured during a longitudinal study with a 3-year follow-up period<xref ref-type="bibr" rid="b15-copd-7-095">15</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">GOLD stage</th><th align="left" valign="top" rowspan="1" colspan="1">Patients (n)</th><th align="left" valign="top" rowspan="1" colspan="1">Age range (yr)<xref ref-type="table-fn" rid="tfn8-copd-7-095">&#x000a7;</xref></th><th align="left" valign="top" rowspan="1" colspan="1">Mean FEV<sub>1</sub><xref ref-type="table-fn" rid="tfn9-copd-7-095">*</xref> decline (mL/yr)<xref ref-type="table-fn" rid="tfn8-copd-7-095">&#x000a7;</xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">49 &#x000b1; 9</td><td align="center" valign="top" rowspan="1" colspan="1">32 &#x000b1; 19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">26</td><td align="left" valign="top" rowspan="1" colspan="1">51 &#x000b1; 9</td><td align="center" valign="top" rowspan="1" colspan="1">90 &#x000b1; 19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="left" valign="top" rowspan="1" colspan="1">53 &#x000b1; 11</td><td align="center" valign="top" rowspan="1" colspan="1">52 &#x000b1; 8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IV</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">49 &#x000b1; 9</td><td align="center" valign="top" rowspan="1" colspan="1">8 &#x000b1; 9</td></tr></tbody></table><table-wrap-foot><fn id="tfn7-copd-7-095"><p><bold>Notes:</bold></p></fn><fn id="tfn8-copd-7-095"><label>&#x000a7;</label><p>Data are presented as mean plus or minus the standard error of the mean;</p></fn><fn id="tfn9-copd-7-095"><label>*</label><p>pre-bronchodilator FEV<sub>1</sub>.</p></fn><fn id="tfn10-copd-7-095"><p><bold>Abbreviation:</bold> yr, year.</p></fn></table-wrap-foot></table-wrap></floats-group></article>